A cross-sectional study was conducted in Baghdad city from the first of March 2022 to the end of February 2023 included 40 patients who were diagnosed with ACS (NSEMI) were included in the analysis of this study, who were admitted to the coronary care unit of our department of cardiology in Al-Yarmuk Teaching Hospital , Baghdad city to evaluate the predictive value of the chemerin protein  for left ventricular systolic dysfunction (LVSD) in patients with acute coronary syndrome-NSTEMI (Non ST elevation myocardial infarction) and the study were also included 40 healthy control blood donors. Patients with clinical evidence of comorbidities were excluded from this study. The study protocol was approved by the local ethics committee of hospital. Complete blood counts, biochemical and cardiac biomarker values were evaluated upon admission to the coronary care unit. Five ml of blood were collected from each patient enrolled in this study. biochemical tests and chemerin level by ELISA (in echocardiography unite. Left ventricular ejection fraction measured using M-mode in the parasternal long-axis view. There was no significant difference between studied groups regarding sex, heart rate, hypertension, DM and BMI (P>0.05). Patients with  NSTEMI have high mean of age and low rate of smoking (P≤0.05). The study showed that chemerin level was elevated significantly in   patients with NSTEMI (372.6 ± 58.4 ng/ml)  as  compared healthy persons (198.5 ± 35.7  ng/dl), (P<0.001). The study showed that the highest mean of chemerin level was recorded in patients with NSTEMI who have EF <40% (382.4 ± 44.2 ng/ml) followed by group who EF 40-505 (301.5±34.4ng/ml)  and the lowest mean was in patients with EF >50% (288.4±35.4 ng/ml) (P<0.001). The study showed  positive  correlation between chemerin level and platelets counts in  patients with NSTEMI and negative correlation of between EF and age patients with NSTEMI.Conclusions: Chemerin has been investigated as a simple a feasible new prognostic inflammatory marker for adverse cardiovascular outcomes in many types of cardiovascular diseases and a high chemerin is a strong and independent predictor for LVSD in patients with NSTEMI.

Keywords: Coronary artery disease; chemerin; EF%; NSTEMI